Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response.
Saved in:
| Title: | Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response. |
|---|---|
| Authors: | Lee U; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Szabova L; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Collins VJ; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Gordon M; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Johnson K; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Householder D; Center for Advanced Preclinical Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Jorgensen S; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Lu L; Center for Advanced Preclinical Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Bassel L; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Elloumi F; Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Peer CJ; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Nelson AE; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Varriano S; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Varma S; Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Roberts RD; Center for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.; Department of Hematology, Oncology and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, United States., Ohler ZW; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Figg WD; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Sharan SK; Center for Advanced Preclinical Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Pommier Y; Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Heske CM; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States. |
| Source: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2024 Oct 24; Vol. 12, pp. 1462840. Date of Electronic Publication: 2024 Oct 24 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2296-634X |
|---|---|
| DOI: | 10.3389/fcell.2024.1462840 |
